{"id":5336,"date":"2026-10-08T08:23:31","date_gmt":"2026-10-08T02:53:31","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-08\/"},"modified":"2026-10-08T08:23:35","modified_gmt":"2026-10-08T02:53:35","slug":"glenmark-share-price-today-2026-10-08","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-08\/","title":{"rendered":"Glenmark Pharmaceuticals in Focus After US Adapalene Gel Launch | 8 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"premarket\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: GLENMARK<\/strong> \u00b7 8 October 2026 \u00b7 Pre-market update<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Previous close<\/div>\n<div>\u20b92,311.00<\/div>\n<\/div>\n<div>\n<div>Previous day change<\/div>\n<div>+0.70%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,320.00 \/ \u20b92,277.30<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>4.94 lakh<\/div>\n<\/div>\n<div>\n<div>Previous trading day<\/div>\n<div>6 October 2026<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Glenmark Pharmaceuticals is in focus after its US subsidiary, Glenmark Therapeutics Inc., announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product targets the over-the-counter dermatology market, which had annual sales of approximately $45.8 million for the 52-week period ending September 5, 2026. Investors will closely watch how this new dispensing option impacts the company&#x27;s US dermatology portfolio performance after market open.<\/li>\n<li>Glenmark Therapeutics Inc., USA, has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs to provide a more convenient dispensing option for consumers. The product&#x27;s active ingredient is comparable to Differin Gel, 0.1%, addressing an OTC market that recorded approximately $45.8 million in annual sales based on Nielsen syndicated data for the 52-week period ending September 5, 2026. Management notes that the launch strengthens the growing U.S. dermatology portfolio by offering consumer-focused healthcare solutions.<\/li>\n<li>Trading volume was 0.91 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Glenmark Pharmaceuticals Company News Before Market Open<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Glenmark Pharmaceuticals is in focus after its US subsidiary, Glenmark Therapeutics Inc., announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product targets the over-the-counter dermatology market, which had annual sales of approximately $45.8 million for the 52-week period ending September 5, 2026. Investors will closely watch how this new dispensing option impacts the company&#x27;s US dermatology portfolio performance after market open.<\/p>\n<p class=\"wt-copy\">The launch of Adapalene Gel USP, 0.1% in new pump packs expands Glenmark&#x27;s US over-the-counter dermatology product offerings. Targeting a segment with approximately $45.8 million in recent annual US market sales highlights potential revenue streams in the consumer health division. The prior session closed up 0.7% at \u20b92311.0 on October 6, 2026, providing a baseline technical reference ahead of trading.<\/p>\n<p class=\"wt-copy\">4.94 lakh shares traded on 6 October 2026. This compares with a 20-day average daily volume of 5.42 lakh shares (0.91 times). The five-day average daily volume was 8.00 lakh shares.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Company-specific context<\/div>\n<div class=\"wt-card-body\"><strong>Glenmark Therapeutics Launches Adapalene Gel USP, 0.1% Pump Packs in the US<\/strong><\/p>\n<p class=\"wt-copy\">The launch of Adapalene Gel USP, 0.1% in new pump packs expands Glenmark&#x27;s US over-the-counter dermatology product offerings. Targeting a segment with approximately $45.8 million in recent annual US market sales highlights potential revenue streams in the consumer health division. The prior session closed up 0.7% at \u20b92311.0 on October 6, 2026, providing a baseline technical reference ahead of trading.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Glenmark Therapeutics Launches Adapalene Gel USP, 0.1% Pump Packs in the US<\/div>\n<div class=\"wt-card-date\">6 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Glenmark Therapeutics Inc., USA, has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs to provide a more convenient dispensing option for consumers. The product&#x27;s active ingredient is comparable to Differin Gel, 0.1%, addressing an OTC market that recorded approximately $45.8 million in annual sales based on Nielsen syndicated data for the 52-week period ending September 5, 2026. Management notes that the launch strengthens the growing U.S. dermatology portfolio by offering consumer-focused healthcare solutions.<\/p>\n<p class=\"wt-copy\">Expands Glenmark&#x27;s footprint in the US over-the-counter dermatology sector, offering a new product option in a market with established annual sales.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">6 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 06, 2026, titled &quot;Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_06102026083500_SEIntimation_06102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">46.65%<\/div>\n<div class=\"wt-note\">46.65% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">20.89%<\/div>\n<div class=\"wt-note\">20.34% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">39.49%<\/div>\n<div class=\"wt-note\">39.63% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1693887_16072026123852_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.76% on 30 June 2026. This compares with 16.80% on 31 March 2026, a change of -0.04 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 37 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND &#8211; HDFC MID-CAP FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">1.76 crore shares \u00b7 6.22%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">INVESCO INDIA CONTRA FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">62.18 lakh shares \u00b7 2.20%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">BANDHAN NIFTY 200 MOMENTUM 30 INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">36.03 lakh shares \u00b7 1.28%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1693887_16072026123852_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Market reaction and trading volume at the open following the announcement of the US product launch.<\/li>\n<li>Price action relative to the prior session&#x27;s high of \u20b92320.0 and low of \u20b9277.3.<\/li>\n<li>Sustained interest in the company&#x27;s US dermatology portfolio developments.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-07\/\">Glenmark Pharmaceuticals Share Price Today: Why GLENMARK Is Falling 1.24% | 7 October 2026 \u2014 7 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-06\/\">Why Glenmark Pharmaceuticals Shares Are Up 0.70% Today | 6 October 2026 \u2014 6 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-05\/\">Why Glenmark Shares Fell 1.54% Today: Sector Consolidation | 5 October 2026 \u2014 5 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/glenmark\/\">More Glenmark Pharmaceuticals news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Glenmark Pharmaceuticals company news?<\/h3>\n<p class=\"wt-copy\">Glenmark Therapeutics Inc., USA, has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs to provide a more convenient dispensing option for consumers. The product&#x27;s active ingredient is comparable to Differin Gel, 0.1%, addressing an OTC market that recorded approximately $45.8 million in annual sales based on Nielsen syndicated data for the 52-week period ending September 5, 2026. Management notes that the launch strengthens the growing U.S. dermatology portfolio by offering consumer-focused healthcare solutions.<\/p>\n<h3>How strong was Glenmark Pharmaceuticals\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">4.94 lakh shares traded, 0.91 times the 20-day average daily volume. The price and volume data are dated 6 October 2026.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-08\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-08\/\"}, \"headline\": \"Glenmark Pharmaceuticals in Focus After US Adapalene Gel Launch | 8 October 2026\", \"description\": \"Glenmark Pharmaceuticals in focus after US subsidiary launches Adapalene Gel USP, 0.1% pump packs. Check pre-market updates, prior session context, and what to.\", \"datePublished\": \"2026-10-08T08:23:16.587774+05:30\", \"dateModified\": \"2026-10-08T08:23:16.587774+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/glenmark-company-news-2026-10-08.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 06, 2026, titled \\\"Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)\\\".\",\"source\":\"NSE\",\"published\":\"06-Oct-2026 08:38:46\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_06102026083500_SEIntimation_06102026.pdf\",\"disclosure_text\":\"Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B\/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com October 6, 2026 To, National Stock Exchange of India Limited, \u201cExchange Plaza\u201d, 5th Floor, Plot No. C\/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai \u2013 400 051 To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 59\/26-27 Our Reference No. 59\/26-27 Dear Sir\/ Madam, Sub: Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC) Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch 1 of Adapalene Gel USP, 0.1% (OTC) in new pump packs. Glenmark\u2019s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin\u00ae2 Gel, 0.1%. According to Nielsen\u00ae syndicated data for the latest 52-week period ending September 5, 2026, the Differin\u00ae Gel, 0.1% (OTC) market3 achieved annual sales of approximately $45.8 million*. Kindly find attached media release which is self- explanatory. Request you to take the same on record. Thanking you. For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS \u2013 28839 Encl: As above Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC) Elmwood Park, New Jersey, October 06, 2026 \u2013 Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Adapalene Gel USP, 0.1% (OTC) in new pump packs . Glenmark\u2019s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin\u00ae2 Gel, 0.1%. According to Nielsen\u00ae syndicated data for the latest 52-week period ending September 5, 2026, the Differin\u00ae Gel, 0.1% (OTC) market3 achieved annual sales of approximately $45.8 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, \u201cThe introduction of Adapalene Gel USP, 0.1% (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio . This launch reflects our commitment to delivering high- quality and affordable healthcare solutions that meet evolving consumer needs.\u201d For product information and how to purchase, please visit: Adapalene Gel USP, 0.1% - 15 g Pump on Amazon Adapalene Gel USP, 0.1% - 45 g Pump on Amazon Adapalene Gel USP, 0.1% - 15 g Pump on Walmart.com Adapalene Gel USP, 0.1% - 45 g Pump on Walmart.com 1Glenmark\u2019s Adapalene Gel USP, 0.1% (OTC) is only marketed for the indications listed in Glenmark\u2019s approved drug facts label. 2This product is not manufactured or distributed by Galderma Laboratories, L.P. and\/or Galderma Holding S.A., distributor of DIFFERIN\u00ae Gel and owner of the registered trademark DIFFERIN\u00ae, respectively. [Galderma does not make or license Glenmark\u2019s product.] 3Market includes brand and all available therapeutic equivalents. Note: IQVIA\u00ae data obtained by Glenmark is only available for all approved RLD indications. Glenmark\u2019s product is only approved for and will only be marketed for the indications listed in Glenmark\u2019s approved label, which may be different than the approved RLD indications. *Nielsen\u00ae NIQ Discover; Syndicated Data for Period Ending September 5, 2026 About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research\u2010led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com. For more information, please contact: India United States Akhila Natarajan mediarelations@glenmarkpharma.com +91 22 4018 9999 Adfactors PR glenmark.ihcp@adfactorspr.com +91 9535635461 Akhila Natarajan mediarelations@glenmarkpharma.com Danielle Hagen danielle@nahigianstrategies.com 202-365-6112\"}],\"shareholding_snapshot\":{\"promoter_pct\":46.65,\"public_pct\":53.35,\"fii_pct\":20.89,\"dii_pct\":18.6,\"mf_pct\":16.76,\"institutional_pct\":39.49,\"noninst_pct\":13.81,\"mf_scheme_count\":37,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"HDFC MUTUAL FUND - HDFC MID-CAP FUND\",\"shares\":17566947,\"pct\":6.22},{\"name\":\"INVESCO INDIA CONTRA FUND\",\"shares\":6217592,\"pct\":2.2},{\"name\":\"BANDHAN NIFTY 200 MOMENTUM 30 INDEX FUND\",\"shares\":3602621,\"pct\":1.28},{\"name\":\"UTI MULTI CAP FUND\",\"shares\":3258742,\"pct\":1.15}],\"period\":\"30-JUN-2026\",\"submission_date\":\"16-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1693887_16072026123852_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":46.65,\"previous_fii_pct\":20.34,\"previous_dii_pct\":19.29,\"previous_mf_pct\":16.8,\"previous_institutional_pct\":39.63,\"previous_mf_scheme_count\":36,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glenmark Pharmaceuticals in focus after US subsidiary launches Adapalene Gel USP, 0.1% pump packs. Check pre-market updates, prior session context, and what to.<\/p>\n","protected":false},"author":1,"featured_media":5335,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Glenmark Pharmaceuticals in Focus After US Adapalene Gel Launch | 8 October 2026","_witty_meta_description":"Glenmark Pharmaceuticals in focus after US subsidiary launches Adapalene Gel USP, 0.1% pump packs. Check pre-market updates, prior session context, and what to.","_witty_primary_phrase":"Glenmark Pharmaceuticals US launch","_witty_reason_label":"Glenmark Therapeutics Launches Adapalene Gel USP, 0.1% Pump Packs in the US","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[37],"class_list":["post-5336","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-glenmark"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=5336"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5336\/revisions"}],"predecessor-version":[{"id":5337,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5336\/revisions\/5337"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/5335"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=5336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=5336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=5336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}